Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 6Hematologic Neoplasms 2Recurrence 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Biphenotypic, Acute 1

Interventions

Cyclophosphamide 104fludarabine 61Methotrexate 50Dexamethasone 47Cytarabine 46fludarabine phosphate 45Vincristine 43blinatumomab 36Whole-Body Irradiation 33Mycophenolic Acid 30Tacrolimus 26Melphalan 26Mercaptopurine 25venetoclax 24Specimen Handling 24Etoposide 24pegaspargase 21Peripheral Blood Stem Cell Transplantation 21Stem Cell Transplantation 20Granulocyte Colony-Stimulating Factor 19Doxorubicin 19Calcium Dobesilate 19Busulfan 19Rituximab 16Prednisone 16Filgrastim 16Daunorubicin 16Asparaginase 16merphos 15Thiotepa 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × Homoharringtonine × 1 year × Clear all
NCT06855810 2025-08-26

CCCG-TALL-2025

Institute of Hematology & Blood Diseases Hospital, China

Phase 2/3 Recruiting
610 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡